JP2009545595A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009545595A5 JP2009545595A5 JP2009522861A JP2009522861A JP2009545595A5 JP 2009545595 A5 JP2009545595 A5 JP 2009545595A5 JP 2009522861 A JP2009522861 A JP 2009522861A JP 2009522861 A JP2009522861 A JP 2009522861A JP 2009545595 A5 JP2009545595 A5 JP 2009545595A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- poloxamer
- heart failure
- item
- effective amount
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 claims description 49
- 229920001983 poloxamer Polymers 0.000 claims description 46
- 229960000502 poloxamer Drugs 0.000 claims description 46
- 238000000034 method Methods 0.000 claims description 44
- 206010019280 Heart failures Diseases 0.000 claims description 22
- 239000000565 sealant Substances 0.000 claims description 12
- 108090000623 proteins and genes Proteins 0.000 claims description 10
- 102000004169 proteins and genes Human genes 0.000 claims description 10
- 230000002861 ventricular Effects 0.000 claims description 8
- 210000004413 cardiac myocyte Anatomy 0.000 claims description 5
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 4
- 229910052791 calcium Inorganic materials 0.000 claims description 4
- 239000011575 calcium Substances 0.000 claims description 4
- 230000003205 diastolic effect Effects 0.000 claims description 4
- 230000003834 intracellular effect Effects 0.000 claims description 4
- 210000000170 cell membrane Anatomy 0.000 claims description 3
- 239000012528 membrane Substances 0.000 claims description 3
- 229920001993 poloxamer 188 Polymers 0.000 claims description 3
- 229940044519 poloxamer 188 Drugs 0.000 claims description 3
- 206010007558 Cardiac failure chronic Diseases 0.000 claims description 2
- 102000004420 Creatine Kinase Human genes 0.000 claims description 2
- 108010042126 Creatine kinase Proteins 0.000 claims description 2
- 101710158332 Diuretic hormone Proteins 0.000 claims description 2
- 101710204261 Diuretic hormone class 2 Proteins 0.000 claims description 2
- 102000001039 Dystrophin Human genes 0.000 claims description 2
- 108010069091 Dystrophin Proteins 0.000 claims description 2
- 102000001708 Protein Isoforms Human genes 0.000 claims description 2
- 108010029485 Protein Isoforms Proteins 0.000 claims description 2
- 102000013394 Troponin I Human genes 0.000 claims description 2
- 108010065729 Troponin I Proteins 0.000 claims description 2
- 102000004987 Troponin T Human genes 0.000 claims description 2
- 108090001108 Troponin T Proteins 0.000 claims description 2
- 230000000747 cardiac effect Effects 0.000 claims description 2
- 230000000694 effects Effects 0.000 claims description 2
- 230000006870 function Effects 0.000 claims description 2
- 230000004217 heart function Effects 0.000 claims description 2
- 230000000302 ischemic effect Effects 0.000 claims description 2
- 238000007789 sealing Methods 0.000 claims description 2
- 210000002966 serum Anatomy 0.000 claims description 2
- 230000002107 myocardial effect Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US83472806P | 2006-08-01 | 2006-08-01 | |
| US60/834,728 | 2006-08-01 | ||
| PCT/US2007/017182 WO2008016640A2 (en) | 2006-08-01 | 2007-08-01 | Use of poloxamer for the prevention and/or treatment of heart failure |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013189091A Division JP2013253103A (ja) | 2006-08-01 | 2013-09-12 | 慢性進行性心不全のための処置 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2009545595A JP2009545595A (ja) | 2009-12-24 |
| JP2009545595A5 true JP2009545595A5 (https=) | 2011-09-29 |
| JP5537152B2 JP5537152B2 (ja) | 2014-07-02 |
Family
ID=38805633
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009522861A Expired - Fee Related JP5537152B2 (ja) | 2006-08-01 | 2007-08-01 | 慢性進行性心不全のための処置 |
| JP2013189091A Withdrawn JP2013253103A (ja) | 2006-08-01 | 2013-09-12 | 慢性進行性心不全のための処置 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013189091A Withdrawn JP2013253103A (ja) | 2006-08-01 | 2013-09-12 | 慢性進行性心不全のための処置 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US9155758B2 (https=) |
| EP (1) | EP2046348B1 (https=) |
| JP (2) | JP5537152B2 (https=) |
| CN (4) | CN103271935A (https=) |
| AU (1) | AU2007281531B2 (https=) |
| CA (1) | CA2659909A1 (https=) |
| WO (1) | WO2008016640A2 (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103271935A (zh) | 2006-08-01 | 2013-09-04 | 普里克萨斯医药股份有限公司 | 泊洛沙姆用于预防和/或治疗心力衰竭的用途 |
| US8372387B2 (en) * | 2007-04-05 | 2013-02-12 | Phrixus Pharmaceuticals, Inc. | Compositions and methods for the treatment of heart failure |
| WO2011156389A2 (en) * | 2010-06-07 | 2011-12-15 | The Regents Of The University Of California | The islet amyloid polypeptide toxic oligomer is a biomarker of heart or kidney failure in type-2 diabetes mellitus |
| CA2927361A1 (en) * | 2013-10-16 | 2015-04-23 | Mast Therapeutics, Inc. | Diuretic induced alterations of plasma volume |
| KR102525493B1 (ko) | 2014-07-07 | 2023-04-25 | 라이프래프트 바이오사이언시즈 인코포레이티드 | 장기 순환 물질이 없는 폴록사머 조성물 및 이의 제조 방법 및 용도 |
| WO2016007542A1 (en) * | 2014-07-07 | 2016-01-14 | Mast Therapeutics, Inc. | Poloxamer therapy for heart failure |
| US9757411B2 (en) | 2014-07-07 | 2017-09-12 | Aires Pharmaceuticals, Inc. | Poloxamer therapy for heart failure |
| EP4178589A4 (en) * | 2020-07-09 | 2024-07-24 | Musc Foundation for Research Development | Methods of protecting cells from insults |
| CN111973623B (zh) * | 2020-08-06 | 2022-04-05 | 温州医科大学 | 心力衰竭靶向治疗的速释制剂 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5198211A (en) * | 1986-05-15 | 1993-03-30 | Emory University | Method of treating myocardial damage |
| US5733572A (en) * | 1989-12-22 | 1998-03-31 | Imarx Pharmaceutical Corp. | Gas and gaseous precursor filled microspheres as topical and subcutaneous delivery vehicles |
| ATE187154T1 (de) * | 1991-03-19 | 1999-12-15 | Cytrx Corp | Polyoxypropylen/polyoxyethylen copolymere mit verbesserter biologischer aktivität |
| WO1992022202A1 (en) | 1991-06-03 | 1992-12-23 | Alpha Therapeutics Corporation | Thrombolytic and perfluorochemical treatment for myocardial infraction |
| US5605687A (en) * | 1992-05-15 | 1997-02-25 | Arch Development Corporation | Methods and compositions of a polymer (poloxamer) for repair of electrical injury |
| US5994348A (en) * | 1995-06-07 | 1999-11-30 | Sanofi | Pharmaceutical compositions containing irbesartan |
| AU1312800A (en) | 1998-10-09 | 2000-05-01 | Cytrx Corporation | Method and composition for treating ischemia and sickle cell anemia |
| US20020013331A1 (en) * | 2000-06-26 | 2002-01-31 | Williams Robert O. | Methods and compositions for treating pain of the mucous membrane |
| US6761824B2 (en) * | 2000-08-17 | 2004-07-13 | Reeve Lorraine E | Process for the fractionation of polymers |
| CA2426811A1 (en) | 2000-10-24 | 2002-08-29 | Smithkline Beecham Corporation | Novel formulations of carvedilol |
| WO2003078603A2 (en) * | 2002-03-15 | 2003-09-25 | Board Of Regents, The University Of Texas System | Strong gene sets for glioma classification |
| US7550155B2 (en) * | 2002-07-29 | 2009-06-23 | Transform Pharmaceuticals Inc. | Aqueous pharmaceutical compositions of 2,6-diisopropylphenol (propofol) and their uses |
| AU2005289520A1 (en) * | 2004-09-27 | 2006-04-06 | Vical Incorporated | Formulations and methods for treatment of inflammatory diseases |
| EP1809272A4 (en) * | 2004-10-18 | 2008-01-02 | Maroon Biotech Corp | METHOD AND COMPOSITIONS FOR TREATING DAMAGES THROUGH FREE RADICALS |
| AU2006216420B2 (en) * | 2005-02-25 | 2010-07-15 | The Regents Of The University Of Michigan | Compositions and methods for treating and preventing cardiomyopathy and heart disease |
| SI1861080T1 (sl) | 2005-03-21 | 2010-08-31 | Santhera Pharmaceuticals Ch | Idebenon za zdravljenje miĺ iäśnih distrofij, njegovo pripravo in farmacevtska uporaba |
| EP2786749A1 (en) | 2006-02-03 | 2014-10-08 | Nicox S.A. | Use of nitrooxyderivative of drug for the treatment of muscular dystrophies |
| CN103271935A (zh) | 2006-08-01 | 2013-09-04 | 普里克萨斯医药股份有限公司 | 泊洛沙姆用于预防和/或治疗心力衰竭的用途 |
| US8372387B2 (en) * | 2007-04-05 | 2013-02-12 | Phrixus Pharmaceuticals, Inc. | Compositions and methods for the treatment of heart failure |
| WO2009078978A2 (en) | 2007-12-14 | 2009-06-25 | Phrixus Pharmaceuticals, Inc. | Compositions containing polyglycidol-based polymers and uses thereof |
| WO2009079562A2 (en) | 2007-12-17 | 2009-06-25 | The Regents Of The University Of Michigan | Compositions and methods for treating and preventing skeletal muscle deficiencies |
| WO2011066201A2 (en) | 2009-11-25 | 2011-06-03 | The Regents Of The University Of Michigan | Methods and systems for treating and preventing cardiac injury in dystrophic subjects |
-
2007
- 2007-08-01 CN CN2013101207279A patent/CN103271935A/zh active Pending
- 2007-08-01 CN CN2011100477182A patent/CN102218077A/zh active Pending
- 2007-08-01 AU AU2007281531A patent/AU2007281531B2/en not_active Ceased
- 2007-08-01 JP JP2009522861A patent/JP5537152B2/ja not_active Expired - Fee Related
- 2007-08-01 EP EP07810983.2A patent/EP2046348B1/en not_active Not-in-force
- 2007-08-01 CA CA002659909A patent/CA2659909A1/en not_active Abandoned
- 2007-08-01 CN CN2013100791323A patent/CN103222984A/zh active Pending
- 2007-08-01 CN CNA2007800367818A patent/CN101534843A/zh active Pending
- 2007-08-01 US US12/309,803 patent/US9155758B2/en not_active Expired - Fee Related
- 2007-08-01 WO PCT/US2007/017182 patent/WO2008016640A2/en not_active Ceased
-
2013
- 2013-09-12 JP JP2013189091A patent/JP2013253103A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009545595A5 (https=) | ||
| Seferović et al. | European Society of Cardiology/Heart Failure Association position paper on the role and safety of new glucose-lowering drugs in patients with heart failure | |
| Kasama et al. | Effect of atrial natriuretic peptide on left ventricular remodelling in patients with acute myocardial infarction | |
| AU2004229049B2 (en) | Treatment Of Hibernating Myocardium Or Pulmonary Congestion | |
| Cimino et al. | Obesity, heart failure with preserved ejection fraction, and the role of glucagon-like peptide-1 receptor agonists | |
| Thompson et al. | Long-term efficacy and safety of elamipretide in patients with Barth syndrome: 168-week open-label extension results of TAZPOWER | |
| DK2683393T3 (en) | TRIPEPTIME COMPOSITIONS AND THEIR USE IN TREATING DIABETES | |
| JP2015506942A5 (https=) | ||
| CA2966756A1 (en) | Methods of treating ckd using predictors of fluid retention | |
| US10004754B2 (en) | ANP fragment adjuvant therapy to standard of care (SOC) diuretic treatment | |
| Choi et al. | Effects of angiotensin receptor blocker at discharge in patients with heart failure with reduced ejection fraction: Korean Acute Heart Failure (KorAHF) registry | |
| TW202245792A (zh) | 靜脈注射伊司他星用於治療急性心臟衰竭 | |
| CN111317811B (zh) | 短胜肽用于治疗或预防高血压及其相关疾病的用途 | |
| JP2023116456A (ja) | 強皮症関連血管障害を治療または改善するための組成物および方法 | |
| EP3072521A1 (en) | Use of recombined ganoderma lucidum immunoregulation protein (rlz-8) in preparing drugs for treating tissue fibrosis | |
| CN103402534A (zh) | 用于治疗充血性心力衰竭的治疗方法 | |
| Katz et al. | Sacubitril-Valsartan (LCZ696) in the treatment of systemic hypertension: an updated review of neprilysin inhibition combined with angiotensin II receptor blockade | |
| WO2016133069A1 (ja) | 心不全の予防又は治療のための医薬 | |
| Liakos et al. | Canagliflozin for type 2 diabetes: an up-to-date evidence summary | |
| Erdoğan et al. | Sinus tachycardia related to tacrolimus after kidney transplantation in children and young adults | |
| Doumas et al. | Left Ventricular Structure and Clinical Characteristics of Non-Dilated Cardiomyopathy | |
| Wilding | Results of the LEAD-2 study in relation to NICE and ADA/EASD guidelines for the treatment of type 2 diabetes in the UK | |
| EA047888B1 (ru) | Применение производных пиперидин мочевины в качестве инотропных агентов | |
| Zakir et al. | Hypertension in African Americans with heart failure: progression from hypertrophy to dilatation; perhaps not | |
| Payne et al. | D52 MOLECULAR INSIGHT INTO PULMONARY HYPERTENSION: The Matrikine Acetylated Proline-Glycine-Proline (acpgp) Couples Extracellular Matrix Fragmentation To Pulmonary Microvascular Remodeling And Pulmonary Hypertension |